bioAffinity Technologies, Inc. (BIAF) has released a new case study showing how its noninvasive diagnostic test, CyPath Lung, provided actionable results that helped a high-risk patient avoid an invasive lung biopsy.
The patient, a 71-year-old former smoker with multiple small pulmonary nodules, faced the possibility of undergoing bronchoscopy or biopsy- procedures that are expensive, invasive, and carry risks. Instead, the CyPath Lung test returned a result of "Unlikely Malignancy," giving both the patient and physician confidence to wait for follow-up imaging. Three months later, scans confirmed the nodules had resolved, indicating benign inflammation.
CyPath Lung uses advanced flow cytometry and AI to analyze sputum samples, incorporating a fluorescent marker that highlights cancer-related cells. In clinical studies, the test has shown 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in nodules less than 20 millimeters.
Management noted that the case illustrates how CyPath Lung can reduce patient anxiety, support physician decision-making, and lower healthcare costs by avoiding unnecessary invasive procedures. The test is marketed as a Laboratory Developed Test (LDT) under CLIA oversight.
The company implemented a 1-for-30 reverse stock split on September 15, 2025. BIAF closed Monday's trading session at $1.91, down 9.91%. In pre-market trading the stock is up $2.20, up 15.64%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.